Andrew Cook, MD
Interventional Pain Medicine · Brownsburg, INNPI 1083956239
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,556 of the $11,812 with a category attached, or 80.9%. 36 manufacturers reported payments, led by Abbott at 30.8% of the total. Reporting peaked in 2019 at $5,166 and has fallen 77.6% since, to $1,157 in 2025.
Across 274 payments — averaging $43.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Vertiflex, Inc.$2K
- Relievant Medsystems, Inc.$1K
- Medtronic$911
- Boston Scientific$696
- ANI Pharmaceuticals, Inc.$524
- plus $3K from 30 others
What the payments were for
- Travel & lodging$2,24119%
- Food & beverage$9,55681%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 52 | $3,637 |
| Vertiflex, Inc. | 11 | $1,897 |
| Relievant Medsystems, Inc. | 8 | $1,037 |
| Medtronic(2 entities) | 10 | $911 |
| Boston Scientific | 42 | $696 |
| ANI Pharmaceuticals, Inc. | 20 | $524 |
| AbbVie(2 entities) | 41 | $509 |
| Nevro Corp. | 7 | $454 |
| Vertos Medical, Inc. | 8 | $389 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $371 |
| Stryker | 2 | $175 |
| Pfizer | 7 | $136 |
| SPR Therapeutics, Inc | 1 | $130 |
| Teva Pharmaceuticals USA, Inc. | 6 | $94 |
| Neurocrine Biosciences, Inc. | 3 | $82 |
| Averitas Pharma Inc. | 3 | $66 |
| Pacira Therapeutics, Inc. | 3 | $63 |
| Blueprint Medicines Corporation | 1 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $56 |
| Si-bone, Inc. | 2 | $53 |
| Lundbeck LLC | 3 | $50 |
| Painteq LLC | 2 | $49 |
| Amgen(2 entities) | 3 | $48 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Vertex | 2 | $45 |
| Biotronik NRO, Inc. | 1 | $43 |
| MML US, Inc. | 2 | $42 |
| Nalu Medical, Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Medline Industries LP | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Valinor Pharma, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Tersera Therapeutics LLC | 1 | $13 |
| Avanos Medical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,812 in reported general payments places this provider in the 80th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 849 | $19,397 |
| BelbucaBuprenorphine Hcl | 14 | $13,716 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 461 | $13,642 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 33 | $6,512 |
| Pregabalin | 259 | $5,711 |
| Gabapentin | 270 | $4,169 |
| Buprenorphine | 12 | $3,954 |
| Oxycodone Hcl | 154 | $2,968 |
| Morphine Sulfate ErMorphine Sulfate | 67 | $2,047 |
| Fentanyl | 12 | $1,298 |
| Tizanidine Hcl | 131 | $1,285 |
| Tramadol Hcl | 176 | $1,175 |
| Diclofenac Sodium | 31 | $1,077 |
| Methocarbamol | 73 | $1,057 |
| Naloxone Hcl | 18 | $1,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $47 | $13,71614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Brownsburg
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
- Edward KowlowitzIndianapolis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.